Boston Scientific Closes Acquisition of Axonics, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Acquisition Announcement: Boston Scientific Corporation has completed its acquisition of Axonics, Inc. for $3.7 billion, enhancing its portfolio in the treatment of urinary and bowel dysfunction through sacral neuromodulation technologies.
Financial Impact: The transaction is expected to have minimal impact on adjusted earnings per share in 2024 and 2025, with potential accretion thereafter, although it may be dilutive on a GAAP basis due to amortization and related charges.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
